Company Description:
52North is a medical technology company on a mission to make urgent care pathways safer and more effective. Awarded breakthrough status for its first product Neutrocheck® by the UK Government in 2024, 52North builds in vitro diagnostic and digital solutions to transform patient journeys in urgent care. Its award-winning, multidisciplinary team is based in Cambridge, UK. 52North is backed by leading UK and US hospital venture funds, Meridian Health Ventures and Cedars-Sinai Intellectual Property company, and other partners, including the University of Cambridge and Macmillan Cancer Support.
[The products mentioned are in development, have not been authorised by regulators and are not currently available for sale. Neutrocheck® is a registered trademark of 52 North Health Ltd.]